Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases. Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases.
Unlike imatinib, another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain. Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is also indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL in combination with chemotherapy.
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2012-02-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT00764309
- Locations
- ๐บ๐ธ
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
๐บ๐ธBoston University School Of Medicine, Boston, Massachusetts, United States
๐บ๐ธMayo Clinic Arizona, Scottsdale, Arizona, United States
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT00754325
- Locations
- ๐บ๐ธ
Kansas City Cancer Center, Llc., Overland Park, Kansas, United States
๐บ๐ธNorthern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
๐บ๐ธUs Oncology Research, Inc., Houston, Texas, United States
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1930
- Registration Number
- NCT00744497
- Locations
- ๐บ๐ธ
Maine Center For Cancer Medicine, Scarborough, Maine, United States
๐บ๐ธJackson Oncology Associates, Pllc, Jackson, Mississippi, United States
๐บ๐ธVa Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideBiological: FilgrastimDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: PrednisoneRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00720109
- Locations
- ๐บ๐ธ
New York Medical College, Valhalla, New York, United States
๐บ๐ธUCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธValley Children's Hospital, Madera, California, United States
Solid Tumors Using Ixabepilone and Dasatinib
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00717704
- Locations
- ๐บ๐ธ
Washington Cancer Institute, Washington, District of Columbia, United States
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 25
- Registration Number
- NCT00706641
- Locations
- ๐บ๐ธ
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธBaylor College of Medicine, Houston, Texas, United States
๐บ๐ธVirginia Oncology Associates, Norfolk, Virginia, United States
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 81
- Registration Number
- NCT00700882
- Locations
- ๐บ๐ธ
Stanford Cancer Center, Stanford, California, United States
๐บ๐ธFlorida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States
๐บ๐ธCancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00696072
- Locations
- ๐บ๐ธ
Florida Cancer Institute - New Hope, Hudson, Florida, United States
๐บ๐ธArizona Oncology Associates D.B.A. Hematology Oncology, Tucson, Arizona, United States
๐บ๐ธCentral Indiana Cancer Centers, Carmel, Indiana, United States
A Phase II Evaluation of Dasatinib (Sprycelยฎ, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT00671788
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธIndiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธSarasota Memorial Hospital, Sarasota, Florida, United States
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 27
- Registration Number
- NCT00662636
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
๐บ๐ธMayo Clinic in Florida, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.